An open-label phase III study to assess the long term safetly profile of GW433908 containing regimens in HIV-1 infected subjects.
Latest Information Update: 04 Jul 2023
At a glance
- Drugs Fosamprenavir (Primary) ; Ritonavir
- Indications HIV-1 infections
- Focus Adverse reactions
- Sponsors ViiV Healthcare
- 22 Jul 2011 Actual end date (October 2010) added as reported by ClinicalTrials.gov.
- 22 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 25 Aug 2009 Additional locations identified as reported by ClinicalTrials.gov.